Evidence map›Paper›PMID 33991328›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2021

Stance of MRD in Non-Hodgkin's Lymphoma and its upsurge in the novel era of cell-free DNA.

S Garg, A Kumar, R Gupta

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

S GargLaboratory Oncology Unit, Dr B.R.A.IRCH, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029, India.
A KumarMedical Oncology Department, National Cancer Institute, AIIMS, Jhajjar, Haryana, India.
R GuptaLaboratory Oncology Unit, Dr B.R.A.IRCH, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029, India. drritugupta@gmail.com.ORCID http://orcid.org/0000-0001-5364-4086

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer genomics has evolved over the years from understanding the pathogenesis of cancer to screening the future possibilities of cancer occurrence. Understanding the genetic profile of tumors holds a prognostic as well as a predictive value in this era of therapeutic surveillance, molecular remission, and precision medicine. Identifying molecular markers in tumors is the current standard of approach, and requires an efficient combination of an accessible sample type and a profoundly sensitive technique. Liquid biopsy or cell-free DNA has evolved as a novel sample type with promising results in recent years. Although cell-free DNA has significant role in various cancer types, this review focuses on its application in Non-Hodgkin's Lymphoma. Beginning with the current concept and clinical relevance of minimal residual disease in Non-Hodgkin's lymphoma, we discuss the literature on circulating DNA and its evolving application in the realm of cutting-edge technology.

Indexed as

Biomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAFlow CytometryGenetic MarkersGenotyping TechniquesHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyLymphomaLymphoma, Non-HodgkinMutationNeoplasm, ResidualPolymerase Chain ReactionPositron-Emission TomographyPrecision MedicineBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNAGenetic MarkersAdvanced molecular techniquesCell-free DNACirculating tumor DNAMinimal residual diseaseNon-Hodgkin’s Lymphoma

Identifiers

PMID33991328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.